Hospital Guides

Choosing a GVHD hospital in China: transplant follow-up and organ-specific care

The search for a hospital becomes more useful when the problem is specific. A patient may need diagnostic review, treatment of steroid-refractory acute GVHD, or coordinated care for chronic lung, eye, oral, or skin involvement. A center's ability to perform stem cell transplantation is relevant background, but the immediate need is management of a post-transplant complication. Bed numbers, research announcements, and professional reputation cannot alone establish that the required service is available for this patient.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

  • Marked breathlessness, severe ongoing diarrhea, inability to maintain food or fluids, bleeding, or serious infection symptoms require timely local assessment. Warning signs after allogeneic transplantation should not be ignored while arranging travel to a preferred city.[1] Transfer or international travel should follow clinical evaluation and confirmation that an appropriate receiving team is prepared to take over.
  • Ocular GVHD can involve tear-film problems, corneal injury, and complications of local treatment. Oral disease can affect pain, eating, and assessment of persistent lesions. EBMT guidance describes dedicated evaluation of these complications; blood tests alone cannot assess them adequately.[7] If visual symptoms or difficulty eating are central to the referral, state that before booking so that relevant appointments can be considered.
  • Ask the hospital to separate consultation, investigation, medicine, procedure, ward, and monitoring charges in an RMB estimate. Items that cannot yet be determined should state the clinical assumption or reassessment needed. A low charge for one item does not establish a lower complete treatment cost, and a more expensive room does not establish more effective GVHD care.

Quick answer

The search for a hospital becomes more useful when the problem is specific. A patient may need diagnostic review, treatment of steroid-refractory acute GVHD, or coordinated care for chronic lung, eye, oral, or skin involvement. A center's ability to perform stem cell transplantation is relevant background, but the immediate need is management of a post-transplant complication. Bed numbers, research announcements, and professional reputation cannot alone establish that the required service is available for this patient.

Full guide

The search for a hospital becomes more useful when the problem is specific. A patient may need diagnostic review, treatment of steroid-refractory acute GVHD, or coordinated care for chronic lung, eye, oral, or skin involvement. A center's ability to perform stem cell transplantation is relevant background, but the immediate need is management of a post-transplant complication. Bed numbers, research announcements, and professional reputation cannot alone establish that the required service is available for this patient.

This article uses official institutional information checked in September 2026 to identify Chinese services that may be approached for clarification and to explain how to compare proposed care. It is not a ranking of GVHD outcomes. Current bed availability, medicine stock, and trial places have not been confirmed. Those details require direct, dated information from the receiving center.

Decide whether the priority is a planned opinion or urgent stabilization

Marked breathlessness, severe ongoing diarrhea, inability to maintain food or fluids, bleeding, or serious infection symptoms require timely local assessment. Warning signs after allogeneic transplantation should not be ignored while arranging travel to a preferred city.[1] Transfer or international travel should follow clinical evaluation and confirmation that an appropriate receiving team is prepared to take over.

For a relatively stable patient, define the consultation question. “Is the skin sclerosis still associated with active inflammation?” or “What is causing the lung-function decline?” gives a center more information than asking whether it is the best hospital. It also helps the family determine whether a distant visit is likely to change a decision or whether the needed care can be coordinated closer to home.

Peking University People's Hospital: clarify the clinical and international routes

The hospital's official English description identifies the Peking University Institute of Hematology and its stem cell transplantation work. This provides a relevant specialist entry point for asking about post-transplant management.[2] Confirm which clinician would assess GVHD, whether patients transplanted elsewhere are accepted, and whether additional organ-specialist reviews can be coordinated.

The hospital's international-patient FAQ describes appointment arrangements and states that it currently cannot provide telemedicine for international patients.[3] Sending records or requesting an appointment should therefore not be represented as a completed remote diagnosis or a guarantee of an online prescription. Ask the hospital to confirm the appropriate consultation route, campus, and required documents. Administrative assistance and a clinician's decision to accept a case are distinct steps.

First Affiliated Hospital of Soochow University: connect academic background with actual care

Soochow University's official hematopoietic stem cell transplantation institute profile identifies its base in the First Affiliated Hospital's hematology department and describes transplant-related immunology, infection, and cellular-therapy research.[4] This supports considering the department for further inquiry. The research institute's office address or academic contact should not be mistaken for a patient clinic or international admission service.

Ask the hospital directly about GVHD follow-up, the accepted age range, relevant organ services, and arrangements for overseas patients. An institutional profile does not confirm a bed today or an open research cohort. Historical transplant volumes and survival figures are not used here to compare hospitals; the practical question is whether this patient's current needs can be met through a confirmed care pathway.

Identify the clinician who will integrate the organ assessments

Chronic GVHD can involve several systems at once. MSK's public description of its GVHD clinic illustrates coordinated assessment, symptom documentation, and functional measurements. It is useful for understanding the information a comprehensive review may bring together, but it does not establish that a particular Chinese hospital operates an identical clinic.[5]

Ask who combines ophthalmology, oral medicine, respiratory, dermatology, and rehabilitation findings when these are needed. Who decides on systemic immune treatment, and who receives notice of a prescription change from another department? If no clinician has an overview, it becomes harder to coordinate infection risk and drug interactions. A clearly assigned responsibility is more informative than the label “multidisciplinary service” by itself.

For lung involvement, ask about physiology as well as imaging

Pulmonary chronic GVHD with bronchiolitis obliterans syndrome requires interpretation of lung function, imaging, infection, and other possible causes. The 2024 adult ERS/EBMT recommendations also address follow-up, rehabilitation, and treatment considerations, supporting collaboration between transplant and respiratory clinicians.[6]

Availability of lung-function testing and timely reassessment may be more relevant than the presence of a particular scanner. Clarify how previous raw lung-function results should be submitted, how existing respiratory support will continue, and who will act on a decline. A chest image that appears unchanged does not by itself complete the evaluation. The center should explain the question each planned investigation is expected to answer.

Eye, oral, and skin symptoms need the right specialist access

Ocular GVHD can involve tear-film problems, corneal injury, and complications of local treatment. Oral disease can affect pain, eating, and assessment of persistent lesions. EBMT guidance describes dedicated evaluation of these complications; blood tests alone cannot assess them adequately.[7] If visual symptoms or difficulty eating are central to the referral, state that before booking so that relevant appointments can be considered.

Skin sclerosis, restricted movement, and genital mucosal problems may require dermatology, rehabilitation, or gynecologic input. NIH supportive-care recommendations address these longer-term needs.[8] Every patient does not need every department, but the hospital should be able to explain which services are appropriate for the actual organ pattern and whether they can be completed during the proposed visit.

Require specific answers about new medicines and cellular products

A center's publication about a cellular treatment does not mean it can provide that intervention routinely to every patient. China's amimestrocel approval has defined age, disease-form, and gastrointestinal-involvement conditions. Another preparation is not equivalent merely because both are described as mesenchymal cells.[9]

The Chinese belumosudil label likewise defines indication, interaction, and monitoring requirements.[10] When a medicine is proposed, ask for the actual product, the basis for its use, continuity of supply, and the tests needed during treatment. The useful output is a deliverable clinical plan. A list of every recently approved overseas drug does not establish that any of them can be accessed or safely continued through the proposed center.

If photopheresis is proposed, confirm the complete process

Extracorporeal photopheresis involves repeated procedures, vascular access, anticoagulation, and post-treatment light protection. Patient information explains these general elements, but cannot confirm equipment, staffing, or appointment capacity in a Chinese hospital.[11] The center itself should state whether treatment is performed there, the expected early attendance pattern, and how response will be reviewed.

Ask how treatment could continue after return home or transfer back to the original hospital and who would manage access-related problems. The ability to arrange one procedure is not proof that the full course is feasible. For a patient needing frequent attendance, reliable continuity may matter more to the eventual benefit than a single visit with a well-known expert.

Separate research activity from an individual's enrollment opportunity

A research-active center may offer additional options for discussion, but each trial has its own disease-stage, prior-treatment, and organ-function requirements. A registry's overall recruitment status does not necessarily mean that a specific center has an available place. Request the study identifier, current cohort information, screening requirements, and expected attendance from the research team.[12]

Also ask about standard treatment if screening is unsuccessful, the plan after withdrawal, and financial responsibilities. Patients should not stop existing medicines independently to fit a study window. Participation in previous research by a hospital does not confer eligibility on a new patient. Research access is one consideration in hospital choice; it should be assessed alongside basic disease stabilization and dependable follow-up.

Make international communication practical

Confirm the language accepted for records, availability of medical interpretation, and how the resulting assessment will be shared with the home clinician. Bring original reports with accurate translations. Generic drug names, dose changes, laboratory units, and biopsy dates need to remain clear. Translating only the diagnosis heading may leave the new team unable to understand why a treatment was changed.

After consultation, request a summary of the current assessment, unresolved questions, prescriptions, and next review. Where several departments or campuses are involved, identify who coordinates the final plan. Service staff can assist with arrangements, but treatment choices and risks need explanation by clinicians with the appropriate responsibility. A helpful coordination service should make that clinical relationship easier to understand.

Compare financial clarity and follow-up responsibility

Ask the hospital to separate consultation, investigation, medicine, procedure, ward, and monitoring charges in an RMB estimate. Items that cannot yet be determined should state the clinical assumption or reassessment needed. A low charge for one item does not establish a lower complete treatment cost, and a more expensive room does not establish more effective GVHD care.

Before leaving, know who will review the next blood count, who will respond to lung-function deterioration, whether the original transplant center remains involved, and where urgent care will be obtained. Ask what happens if a medicine or test cannot be supplied at home. These questions can reveal a gap before it causes an interruption.

The suitable hospital is one that can connect the current clinical question with services it can actually deliver and a workable next stage of care. That makes the choice assessable through verified arrangements rather than a “best hospital” label whose meaning and comparison group are unclear.

References

  1. MSK. Warning symptoms after allogeneic transplant discharge: https://www.mskcc.org/cancer-care/patient-education/leaving-hospital-after-your-allogeneic-transplant
  2. Peking University People's Hospital. Official hematology institute profile: https://english.pkuph.cn/Institutes_detail/383.html
  3. Peking University People's Hospital. International patient FAQ: https://english.pkuph.cn/care/overview_g7yU_57.html
  4. Soochow University Institute of Hematopoietic Stem Cell Transplantation. Institutional profile: https://ibmt.suda.edu.cn/32220/list.htm
  5. MSK. Introduction to the GVHD clinic, updated in 2026: https://www.mskcc.org/cancer-care/patient-education/introduction-graft-versus-host-disease-gvhd-clinic
  6. ERS/EBMT. Adult pulmonary chronic GVHD-related BOS recommendations: https://publications.ersnet.org/lookup/pmid/38485149
  7. EBMT Handbook. Ocular and oral complications: https://www.ncbi.nlm.nih.gov/books/NBK608294/
  8. NIH. Ancillary therapy and supportive care in chronic GVHD: https://pmc.ncbi.nlm.nih.gov/articles/PMC4821166/
  9. NMPA. Amimestrocel injection approval information: https://english.nmpa.gov.cn/2025-06/11/c_1101502.htm
  10. Sanofi China. Belumosudil prescribing information, 2026: https://www.sanofi.cn/assets/dot-cn/pages/docs/products/prescription-products/rezurock-cn-20260122.pdf
  11. MSK. Photopheresis patient information: https://www.mskcc.org/cancer-care/patient-education/frequently-asked-questions-about-photopheresis
  12. ClinicalTrials.gov. Example chronic GVHD clinical study: https://clinicaltrials.gov/study/NCT06585774

Related guides